ALK and lymphoma: The utility of TrkA as a potential therapeutic target in NPM‐ALK+ T‐cell lymphoma was underscored when blockade of TrkA signaling using a small‐molecule inhibitor decreased cell proliferation, viability, and anchor‐independent colony formation of these lymphoma cells.